argenx SE
disclosures the phase adapt and adapt studies were funded by has received research support honoraria and nonfinancial support from | argenx SE
Company
Deck Type
Sector
Industry
Deck date
April 2022
Slide
2 of 10
Related slides by other companies
AbCellera
IPO
December 2020
ust help everyone share in the success partner clinical phase phase pee tell building a diversified portfolio of milestones royalties primary value driver discovery research fees milestones near term revenue from research rill multimillion dollar potential clinical and commercial milestone payments majority of risk adjusted value from royalty on commercial therapeutic | AbCellera
Other recent decks by argenx SE
See all presentations (28 decks)
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io